Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

GIP/GLP-1 Coagonist III is under clinical development by Eli Lilly and Co and currently in Phase I for Cardiometabolic Disease.

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Following billionaire investors isn't as difficult as you might imagine thanks to quarterly reporting required by the ...

Recent pharmaceutical innovations have opened a new path for weight loss through drugs based on gut hormones such as GLP-1 ...

The effects that a pause may have on your body may depend on why you're taking the medication in the first place.

Research tells us that eating enough protein and staying physically active can be helpful in reducing the amount of non-fat ...

Other approaches that are in development include fibroblast growth factor (FGF) mimetics such as FGF21-targeting candidates ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...